Original site: www.cdc.gov/acip-recs/hcp/vaccine-specific/covid-19.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.

[More]
About Us Report Bug

RestoredCDC.org Comparison

Removed: Line removed from cdc.gov. Specific word removals are highlighted.
Added: Line added to cdc.gov. Specific word additions are highlighted.
Injected: Line or disclaimer added by RestoredCDC.org.
Unchanged: Line unchanged.
Original site: www.cdc.gov/acip-recs/hcp/vaccine-specific/covid-19.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.
[More]
About Us Report Bug Compare Content
Skip directly to site content Skip directly to search Skip directly to On This Page
An official website of the United States government
Here's how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
ACIP Vaccine Recommendations and Guidelines
Explore Topics
Search
Search
Clear Input
Health Care Providers
* Vaccine-Specific Recommendations
* Archived ACIP Recommendations
* Recommendations by Date
* View all
Related Topics:
Advisory Committee on Immunization Practices (ACIP) | ACIP GRADE Handbook | Vaccines & Immunizations
View All
search close search
search
ACIP Recommendations Menu Close
ACIP Recommendations Menu
search
Health Care Providers
* Vaccine-Specific Recommendations
* Archived ACIP Recommendations
* Recommendations by Date
* View All
Related Topics
* Advisory Committee on Immunization Practices (ACIP)
* ACIP GRADE Handbook
* Vaccines & Immunizations
View All ACIP Recommendations
Vaccine-Specific Recommendations Archived ACIP Recommendations Recommendations by Date View All
July 25, 2024
December 18, 2024
ACIP Recommendations: COVID-19 Vaccine
Advisory Committee on Immunization Practices (ACIP)
Key points
* The Advisory Committee on Immunization Practices (ACIP) develops recommendations on how to use vaccines to control disease in the United States.
* These recommendations become official CDC policy once adopted by CDC's Director.
* Learn about current and historical ACIP recommendations for COVID-19 vaccine.
Published in Morbidity and Mortality Weekly Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
Keep Reading: See Clinical Considerations for Use of COVID-19 Vaccines
CURRENT COVID-19 Vaccine Recommendations
MMWR, December 12, 2024. Vol 73 (49); 1118-1123
Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Print version
MMWR, September 10, 2024. Vol 73 (37);819-824
Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025.
Print version
ARCHIVED COVID-19 Immunization Publications
For your convenience, these archived publications can be used for historical and research purposes.
MMWR, April 25, 2024, Vol 73(16);377-381
Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Print version
MMWR, October 20, 2023, Vol 72(42);1140–1146
Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
Print version
MMWR, June 16, 2023, Vol 72(24);657–662
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
Print version
MMWR, November 11, 2022, Vol 71(45); 1436-1441
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 | MMWR (cdc.gov)
Print version
MMWR, August 4, 2022, Vol 71(31); 988-992
Interim Recommendation of the Advisory Committee on Immunization Practices for use of the Novavax COVID-19 vaccine in persons aged 18 years and older— United States, July 2022
Print version
MMWR, June 28, 2022, Vol 71(26);859–868
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
Print version
MMWR, March 18, 2022, Vol 71(11);416–421
Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
Print version
MMWR, January 21, 2022, Vol 71(3);90–95
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices – United States, December 2021
Print version
MMWR, November 5, 2021, Vol 70(45);1579–1583
Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Print version
MMWR, November 5, 2021, Vol 70(44);1545–1552
Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
Print version
MMWR, September 24, 2021, Vol 70(38);1344–1348
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
Print version
MMWR, August 13, 2021, Vol 70(32);1094-1099
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
Print version
MMWR, July 9, 2021, Vol 70(27);977–982
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Print version
MMWR, May 14, 2021, Vol 70(20);749–752
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
Print version
MMWR, April 30, 2021, Vol 70(17);651-656
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
Print version
MMWR, March 2, 2021, Vol 70(9);329–332
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
Print version
MMWR, December 22, 2020, Vol 69(5152);1657-1660
The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020
Print version
MMWR, December 20, 2020, Vol 69(5152);1653-1656
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
Print version
MMWR, December 13, 2020, Vol 69(50);1922-1924
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
Print version
MMWR, December 3, 2020, Vol 69(49);1857-1859
The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
Print version
On This Page
* Published in Morbidity and Mortality Weekly Report (MMWR)
* CURRENT COVID-19 Vaccine Recommendations
* ARCHIVED COVID-19 Immunization Publications
Related PagesVaccine-Specific Recommendations
Related Pages
*
 
* Vaccine-Specific Recommendations
* Anthrax
* Cholera
*
* Dengue
* DTaPHiba>
* DTaP/IPV/Hib/HepB
View All
View All ACIP Recommendations
 
Dengue
Back to Top
December 18, 2024
July 25, 2024
Sources Print Share
Facebook LinkedIn Twitter Syndicate
Content Source:
National Center for Immunization and Respiratory Diseases (NCIRD)
Related PagesVaccine-Specific Recommendations
Related Pages
*
 
* Vaccine-Specific Recommendations
* Anthrax
* Cholera
*
* Dengue
* DTaPHiba>
* DTaP/IPV/Hib/HepB
View All
View All ACIP Recommendations
Back to Top
ACIP Recommendations
Find a complete list of ACIP recommendations published in the MMWR.
View All
* Vaccine-Specific Recommendations
* Archived ACIP Recommendations
* Recommendations by Date
Sign up for Email Updates
Contact Us
Contact Us
* Call 800-232-4636
* Contact CDC
About CDC
About CDC
* Pressroom
* Organization
* Budget & Funding
* Careers & Jobs
Policies
* Accessibility
* External Links
* Privacy
* Web Policies
* FOIA
* OIG
* No Fear Act
* Nondiscrimination
* Vulnerability Disclosure Policy
Languages
Languages
* Español
Language Assistance
* Español
* 繁體中文
* Tiếng Việt
* 한국어
* Tagalog
* Русский
* العربية
* Kreyòl Ayisyen
* Français
* Polski
* Português
* Italiano
* Deutsch
* 日本語
* فارسی
* English
Archive
* CDC Archive
* Public Health Publications
Contact Us
Contact Us
* Call 800-232-4636
* Contact CDC
About CDC
* Pressroom
* Organization
* Budget & Funding
* Careers & Jobs
* About CDC
Policies
* Accessibility
* External Links
* Privacy
* Web Policies
* FOIA
* OIG
* No Fear Act
* Nondiscrimination
* Vulnerability Disclosure Policy
Languages
Languages
* Español
Language Assistance
* Español
* 繁體中文
* Tiếng Việt
* 한국어
* Tagalog
* Русский
* العربية
* Kreyòl Ayisyen
* Français
* Polski
* Português
* Italiano
* Deutsch
* 日本語
* فارسی
* English
Archive
* CDC Archive
* Public Health Publications
HHS.gov USA.gov
Note: Comparison ignores leading/trailing whitespace and certain script/tracking codes. Word-level highlighting (optional above) only applies to changed lines.